Vycor Medical, Inc. filings document its financial-result disclosures as a Delaware operating company. Recent Form 8-K reports under Item 2.02 furnish press releases for annual and interim results, with related exhibits under Item 9.01. The filings also describe non-GAAP presentations used in those releases, including Cash Operating Expenses and Cash Operating Loss reconciled to comparable GAAP measures and adjusted for depreciation and non-cash stock compensation.
Vycor Medical, Inc. reported results for the three months ended March 31, 2026, highlighted in an earnings press release furnished with this report. Revenue was $458,540, up 5% from $436,378 in 2025, driven mainly by international growth in the Vycor Medical (VBAS) division.
VBAS revenue was $440,441, a 5% increase, while NovaVision generated $18,099 with high gross margin. On a GAAP basis, total operating expenses were $329,345, producing operating income of $45,808 and a net loss available to common stockholders of $(142,077), or $(0.00) per share. Non-GAAP cash operating expenses were $315,365, non-GAAP operating profit was $59,788, and non-GAAP net loss was $(128,097), reflecting improvements versus 2025.
Vycor Medical, Inc. reported Q1 2026 revenue of $458,540, up modestly from 2025, and net income of $20,108. After $162,185 of preferred dividends, common shareholders recorded a net loss of $142,077.
Cash improved to $173,634, but the company has a working capital deficit of $4,297,001 and total liabilities of $5,083,027. Management discloses “substantial doubt” about Vycor’s ability to continue as a going concern, citing heavy related-party obligations and a $300,000 EuroAmerican note at 16% interest maturing on June 30, 2026.
Vycor Medical, Inc. reported 2025 revenue of $1,863,400, up 17% from 2024, driven mainly by international growth in its Vycor Medical (VBAS) neurosurgery business. VBAS revenue reached $1,796,070, an 18% increase, while NovaVision contributed $67,330.
Gross profit rose to $1,561,107 with an 83% margin, down from 89% in 2024 due to new production, shipping, and higher international mix. On a GAAP basis, Vycor generated operating income of $33,900 but recorded a net loss available to common stockholders of $396,796, or $0.01 per share, after preferred dividends.
Excluding non-cash depreciation and stock-based compensation, non-GAAP cash operating expenses were $1,415,226 and non-GAAP operating profit improved to $145,881. Non-GAAP net loss available to common shareholders narrowed to $284,815, or $0.01 per share, indicating better underlying operating performance despite continued net losses.
Vycor Medical, Inc. reports full-year 2025 results and highlights significant going concern risks. Total revenue reached $1,863,400, up from 2024, driven mainly by Vycor Medical product sales of $1,796,070, an 18% increase. Consolidated gross profit was $1,561,107, with Vycor Medical posting an 83% gross margin and NovaVision 93%.
The company recorded a modest net loss of $72,426, but after $324,370 of cumulative preferred dividends on Series D stock, net loss available to common stockholders was $396,796. Cash was only $86,982 at December 31, 2025, against a working capital deficiency of $4,218,046, including $3,658,382 of related-party liabilities. Auditors and management state these factors raise substantial doubt about Vycor’s ability to continue as a going concern.
Vycor Medical, Inc. furnished an Item 2.02 report announcing a press release with financial results for the three and nine months ended September 30, 2025.
The release includes non-GAAP measures—Cash Operating Expenses and Cash Operating Loss—which exclude Depreciation and non-cash Stock Compensation, with reconciliations to comparable GAAP measures. The press release is attached as Exhibit 99.1, and the information is furnished and not deemed “filed” under the Exchange Act.
Vycor Medical (VYCO) filed its quarterly report, highlighting higher sales alongside continued financial pressure. Q3 revenue was $513,792, up 31% year over year, led by Vycor Medical products, with gross profit of $451,932. The company produced operating income of $32,085 versus a prior-year loss, and reported net income of $4,936 before preferred dividends.
After $162,185 in cumulative preferred dividends for the quarter, net loss available to common stockholders was $(157,249). Cash was $64,230 and the working capital deficit was $(4,152,481). Total liabilities stood at $4,965,388 and stockholders’ deficiency at $(4,024,193). Management disclosed substantial doubt about the company’s ability to continue as a going concern.
The filing notes a $300,000 EuroAmerican note (accrued interest $556,932) extended to March 31, 2026 and an SBA EIDL balance of $136,745. There were 33,372,796 common shares outstanding as of November 14, 2025.